Novartis’ NVA237 improves lung function in pulmonary disease patients

Swiss drug maker Novartis said results from a phase three study remarkably improved lung function in a similar way to a rival drug.

Read more »

Inherent value to be “developed and extracted” at Amphion

Amphion Innovations (LON:AMP) said it believes there is “significant inherent value to be developed and extracted” from its partner companies, […]

Read more »

Neostem’s Suzhou Eyre receives Chinese Regulatory Approval For 6th Production Line

NeoStem announced Monday that its subsidiary, Suzhou Eyre Pharmaceuticals, has received approval for its sixth production line.

Read more »

ImmunoCellular Therapeutics Expands Phase 2 Trial For Brain Cancer Treatment

ImmunoCellular Therapeutics has expanded the number of sites for its phase two clinical trial ofa potential vaccine treatment for brain cancer.

Read more »

OXiGENE Releases Promising Phase Two Data For Lung Cancer Drug

OXiGENE shares rose in pre-market trading Monday

Read more »

Emergent BioSolutions Acquires Rights To Lymphoma Drug

Emergent BioSolutions has acquired the rights to Zanolimumab, an investigational and late-stage antibody cancer therapy.

Read more »

YM BioSciences Receives Orphan Drug Designation In EU For Myelofibrosis Treatment

YM BioSciences has received orphan drug designation from the European Commission for CYT387, a treatment for myelofibrosis, a type of chronic leukemia.

Read more »

ReNeuron Treats Third Stroke Patient In Phase I Trials Of Stem Cell Therapy

ReNeuron said this morning the last of the stroke patients in the initial dosing group has been treated with the group’s new stem cell therapy.

Read more »

NeoStem To Drive Shareholder Value, Says Rodman & Renshaw

NeoStem said Thursday that equity research firm Rodman & Renshaw re-iterated the multi-faceted stem cell company’s market outperform rating, based on “multiple milestones to drive shareholder value”.

Read more »

Renovo Actively Progressing With Plans To Maximize Returns After Juvista Failure

Renovo Group (LON:RNVO) confirmed today it will be left with £33 million if it presses ahead with plans to reduce its headcount by 100.

Read more »